3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
4
Recurrence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Diseases
1
Anemia
1
Amyloidosis
1
Interventions
Rituximab
2
Lenalidomide
2
umbralisib
1
ublituximab
1
tisagenlecleucel
1
tazemetostat
1
tafasitamab
1
selinexor
1
prednisolone phosphate
1
prednisolone acetate
1
polatuzumab vedotin
1
Vincristine
1
Prednisone
1
Prednisolone
1
Methylprednisolone
1
Doxorubicin
1
Cyclophosphamide
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
Appointments and Schedules
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Lymphoma, Large B-Cell, Diffuse
×
Cyclophosphamide
×
Clear all
NCT03274492
2026-05-08
POLARIX
Hoffmann-La Roche
Phase 3
Completed
1,000 enrolled
1 FDA